Analytical Data
-
Gene name
HLA-A*02:01&B2M&PRAME(MMNDQLMFL) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & PRAME (MMNDQLMFL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&MMNDQLMFL
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is a highly prevalent human leukocyte antigen (HLA) allele that plays a critical role in presenting peptides to CD8+ T cells, thus enabling immune surveillance against tumors and infections. The β2-microglobulin (B2M) molecule is essential for the structural stability and function of the HLA-A*02:01 complex. PRAME (Preferentially Expressed Antigen in Melanoma) is a Cancer/testis (CT) antigen that is normally expressed in testes and is often overexpressed in various malignancies, particularly melanoma. The specific peptide MMNDQLMFL derived from PRAME has been identified as a strong candidate for T cell-mediated immunotherapy due to its ability to elicit robust immune responses. The study of the HLA-A*02:01/B2M/PRAME(MMNDQLMFL) monomer recombinant protein provides vital insights into the mechanisms of epitope presentation, T cell activation, and the potential for developing targeted cancer immunotherapies. By recombinantly producing this complex, researchers aim to enhance our understanding of T cell interactions with tumor antigens, paving the way for novel therapeutic strategies that could improve the efficacy of cancer vaccines and adoptive T cell therapies. The structure and function characterization of this recombinant protein can also facilitate the exploration of immune escape mechanisms employed by tumors, ultimately contributing to more effective cancer treatment modalities.
